Targeted therapies

Questions discussed in this category

Do you consider using 160 mg osimertinib in patients with EGFR-positive metastatic NSCLC to the brain?

1 Answer available

How do you manage a patient with metastatic NSCLC whose initial mutation testing was limited or results are no longer available?

How do you operationalize finding biomarker information in EHRs/testing portals, either for your own patients or if they have changed providers? If a...

4 Answers available

What are your treatment considerations for a patient with stage IVb NSCLC who is KRAS G12C mutated and PD-L1 high (>50%)?

3 Answers available

How do you approach treatment sequencing in KRAS G12C NSCLC?

Is there evidence or experience to support use of targeted therapy for KRAS G12C mutated NSCLC as first line in place of chemotherapy?

3 Answers available

Are there best practices for managing or mitigating toxicity from sotorasib such as hyperbilirubinemia or edema?

3 Answers available

What data do you view as most impactful to treatment decisions in 1L metastatic ccRCC?

How do you weigh the various efficacy endpoints in the trials of novel combinations in ccRCC? Are there specific clinical populations that you ...

3 Answers available

In stage II/III node positive patients with driver mutations positive NSCLC who are not surgical candidates and are unlikely to tolerate concurrent chemotherapy and radiation, would you consider radiation alone, TKI alone, or would you ever consider TKI + RT?

What would be the treatment duration if using oral TKI?

1 Answer available

How do you approach patients with driver mutation positive, Stage IV NSCLC who don't benefit from upfront first-line TKI?

Although a small subset, do you generally move these patients directly on to chemotherapy +/- immunotherapy or does it depend on the specific mutation...

1 Answer available

Should 3 years of adjuvant osimertinib be the standard of care for resected Stage IB-IIIA EGFRm NSCLC?

6 Answers available

How would you treat refractory diarrhea in a patient with low grade serous ovarian cancer treated with Trametinib?

Literature regarding treatment of diarrhea due to Trametinib is limited and does not address safety of Lomotil.

1 Answer available

How do you approach a patient who responded to first line osimertinib but develop an isolated progressing lesion that retains sensitizing EGFR mutation but develops MET amplification?

Would you continue osimertinib after radiation therapy, switch to crizotinib, or consider chemotherapy +/- immunotherapy?

1 Answer available

Papers discussed in this category

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-12-01

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.

N Engl J Med, 2020 Sep 19

Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer.

J Clin Oncol, 2020 Dec 04

Lessons From ADAURA on Adjuvant Cancer Drug Trials: Evidence, Ethics, and Economics.

The New England journal of medicine, 2012-07-12

Improved survival with MEK inhibition in BRAF-mutated melanoma.

The New England journal of medicine, 2018-05-31

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

The New England journal of medicine, 2018-06-14

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

Annals of oncology : official journal of the European Society for Medical Oncology, 2019-08-01

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.

Clin Lung Cancer, 2021 Jan 27

Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression.

Eur J Cancer, 2021 Apr 01

Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial.

Lancet Oncol, 2019 Oct 25

Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.

Cancer, 2022 Apr 05

Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.

Lancet Oncol, 2021 Jan 18

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.

The New England journal of medicine, 2016-11-10

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

J Clin Oncol, 2019 Dec 06

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study.

Ann Oncol, 2020 Jul 05

A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.

J Thorac Oncol, 2021 Aug 19

A Phase II Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis From NSCLC: Results for the T790M Cohort of the OCEAN Study (LOGIK1603/WJOG9116L).

Clin Transl Sci, 2023 Feb 19

Brain exposure of osimertinib in patients with EGFRm NSCLC and brain metastases: a PET and MRI study.

Related Topics